Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 19/20 | 0.52 |
| ▸ | PLG | P00747 | 17/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 7/20 | 0.52 |
| ▸ | F2 | P00734 | 6/20 | 0.52 |
| ▸ | F10 | P00742 | 6/20 | 0.52 |
| ▸ | PLAT | P00750 | 3/20 | 0.45 |
| ▸ | HPN | P05981 | 3/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.45 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.45 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL250043 | 0.99 | PLAU (0.51) | PLAUPLGST14F2F10 | |
| SCHEMBL2953288 | 0.89 | PLAU (0.48) | PLAUPLGST14F2F10 | |
| Hydrochloric Acid SCHEMBL4451933 | 0.88 | PLAU (0.48) | PLAUPLGST14F2F10 | |
| SCHEMBL4619934 | 0.87 | PLAU (0.44) | PLAUPLGST14F2F10 | |
| SCHEMBL7058121 | 0.85 | PLG (0.43) | PLAUPLGST14F2F10 | |
| SCHEMBL6129266 | 0.75 | PLAU (0.61) | PLAUPLGST14F2F10 | |
| SCHEMBL5309785 | 0.74 | PLAU (0.37) | PLAUPLGST14F2F10 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL3660147 | 0.71 | PLAU (0.58) | PLAUPLGST14F2F10 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2874625 | 0.70 | PLAU (0.80) | PLAUPLGST14F2F10 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL4606324 | 0.70 | PLAU (0.80) | PLAUPLGST14F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463654-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2019-11-05 | — | — | US | claimed |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD (IL) | 2018-05-10 | — | — | US | claimed |
| US-9089532-B2 | Stable dosage form of phenylalanine derivatives | WILEX AG (DE) | 2015-07-28 | — | — | US | claimed |
| EP-1799265-B1 | STABLE DOSING FORM OF PHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2010-09-08 | — | — | EP | claimed |
| US-7342018-B2 | Urokinase inhibitors and uses thereof | WILEX AG (DE) | 2008-03-11 | — | — | US | claimed |
| EP-1799265-A1 | STABLE DOSING FORM OF PHENYLALANINE DERIVATIVES | Wilex AG (DE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006032461-A1 | STABLE DOSING FORM OF PHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2006-03-30 | — | — | WO | claimed |
| EP-1534283-B1 | FORMULATION OF LIPOSOMAL DERIVATIVES OF PHENYLALANINE | WILEX AG (DE) | 2005-12-14 | — | — | EP | claimed |
| US-20040138233-A1 | Novel urokinase inhibitors | WILEX AG (DE) | 2004-07-15 | — | — | US | claimed |
| EP-1264828-B1 | Inhibitor of urokinase | WILEX AG (DE) | 2004-04-14 | — | — | EP | claimed |
| US-6680320-B2 | ANTITUMOR AGENTS | WILEX AG (DE) | 2004-01-20 | — | — | US | claimed |
| US-20030013723-A1 | Antitumor agents | WILEX AG | 2003-01-16 | — | — | US | claimed |
| EP-1098651-B1 | NOVEL UROKINASE INHIBITORS | WILEX AG (DE) | 2003-01-08 | — | — | EP | claimed |
| EP-1264828-A1 | New inhibitor of urokinase | Wilex AG (DE) | 2002-12-11 | — | — | EP | claimed |
| US-20240108643-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD (IL) | 2024-04-04 | — | — | US | disclosed |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-11633385-B2 | Combination compositions for treatment of cancer | REDHILL BIOPHARMA LTD. (IL) | 2023-04-25 | — | — | US | disclosed |
| US-20030013723-A1 | Antitumor agents | WILEX AG | 2003-01-16 | — | — | US | disclosed |
| EP-1098651-B1 | NOVEL UROKINASE INHIBITORS | WILEX AG (DE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1264828-A1 | New inhibitor of urokinase | Wilex AG (DE) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138233-A1 | Novel urokinase inhibitors | PLAU, PLAUR, DNPEP | PLAU 1/4885PLG 22/4885ST14 333/4885 |
| US-20240108643-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | EIF2AK2, RNMT, FBL | PLAU 1794/4885PLG 2036/4885ST14 2993/4885 |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TPMT, KRAS, ACE | PLAU 3501/4885PLG 4797/4885ST14 2097/4885 |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | SPHK2, SPHK1, S1PR2 | PLAU 1672/4885PLG 1967/4885ST14 2059/4885 |
| US-20030013723-A1 | Antitumor agents | DNPEP, PLAU, ENPEP | PLAU 2/4885PLG 50/4885ST14 165/4885 |
| US-11633385-B2 | Combination compositions for treatment of cancer | KRAS, TPMT, CYP2D6 | PLAU 4148/4885PLG 4692/4885ST14 2067/4885 |
| US-10463654-B2 | Combination therapies for treating cancer | TPMT, KRAS, ACE | PLAU 3501/4885PLG 4797/4885ST14 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.